Walter Jose Gomes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Walter Jose Gomes has a total of 547 co-authors. Here are the top co-authors by number of shared publications:
- Solange Guizilini
Postgraduate Program in Cardiology, Universidade Federal de São Paulo (UNIFESP), São Paulo 04024-000, SP, Brazil
30 shared publications Enio Buffolo
17Hospital Universitário de Santa Maria, Santa Maria, RS, Brazil
25 shared publications- Ross Arena
University of Illinois Chicago
16 shared publications - Domingo Marcolino Braile
Editor-in-Chief - BJCVS Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, SP, Brazil and Universidade de Campinas (UNICAMP), Campinas, SP, Brazil
13 shared publications Francisco A. Alves
OSS-SPDM
10 shared publicationsDouglas W. Bolzan
Cardiovascular and Surgery Discipline, Sao Paulo Hospital, Escola Paulista de Medicina, Federal University of Sao Paulo, Sao Paulo, Brazil
9 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5913
Evaluation of the Molecular Docking of Potential Targets and the Time-Dependent Myocardial Effects of Omeprazole in Normotensive and Spontaneously Hypertensive Rats Subjected to Cardiac Ischemia and Reperfusion
Proton pump inhibitors (PPIs) are widely prescribed for acid-related disorders and are generally considered safe for short-term use. However, increasing experimental and clinical evidence suggests potential cardiovascular effects associated with chronic exposure, possibly related to endothelial dysfunction and impaired nitric oxide bioavailability. Therefore, we decided to investigate whether the cardiovascular effects of omeprazole are dependent on the timing of administration in a model of cardiac ischemia–reperfusion (CIR) in normotensive Wistar rats (NWR) and spontaneously hypertensive rats (SHR). Twelve- to sixteen-week-old male NWR and SHR were allocated into four groups: (1) SHAM: NWR and SHR were submitted to surgery with no ischemia; (2) (SS + CIR): NWR and SHR were treated with a 0.9% saline solution and submitted to CIR; and (3) (OME + ISQ): NWR and SHR were treated with 10 mg/kg i.v. omeprazole (OME) before cardiac ischemia and submitted to CIR or (4) after cardiac ischemia but before cardiac reperfusion (ISQ + OME). Electrocardiograms were monitored to assess ventricular arrhythmias (VA), atrioventricular block (AVB), and lethality (LET). Serum creatine kinase-MB (CK-MB) levels were quantified, and histopathological analyses were performed to evaluate the degree of myocardial injury in the different study groups. Administration of OME prior to cardiac ischemia increased the incidence of VA, AVB, LET, and serum CK-MB levels in both NWR and SHR. In contrast, administration before cardiac reperfusion did not exacerbate cardiac injury and was associated with the attenuation of electrophysiological instability. Histopathological findings corroborated the biochemical and functional outcomes. OME, when administered prior to cardiac ischemia, worsens both cardiac arrhythmias and myocardial injury; however, administration immediately prior to cardiac reperfusion does not increase cardiac arrhythmias and decreases myocardial injury in both NWR and SHR.
- 30 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5913
Open AccessEvaluation of the Molecular Docking of Potential Targets and the Time-Dependent Myocardial Effects of Omeprazole in Normotensive and Spontaneously Hypertensive Rats Subjected to Cardiac Ischemia and Reperfusion
Proton pump inhibitors (PPIs) are widely prescribed for acid-related disorders and are generally considered safe for short-term use. However, increasing experimental and clinical evidence suggests potential cardiovascular effects associated with chronic exposure, possibly related to endothelial dysfunction and impaired nitric oxide bioavailability. Therefore, we decided to investigate whether the cardiovascular effects of omeprazole are dependent on the timing of administration in a model of cardiac ischemia–reperfusion (CIR) in normotensive Wistar rats (NWR) and spontaneously hypertensive rats (SHR). Twelve- to sixteen-week-old male NWR and SHR were allocated into four groups: (1) SHAM: NWR and SHR were submitted to surgery with no ischemia; (2) (SS + CIR): NWR and SHR were treated with a 0.9% saline solution and submitted to CIR; and (3) (OME + ISQ): NWR and SHR were treated with 10 mg/kg i.v. omeprazole (OME) before cardiac ischemia and submitted to CIR or (4) after cardiac ischemia but before cardiac reperfusion (ISQ + OME). Electrocardiograms were monitored to assess ventricular arrhythmias (VA), atrioventricular block (AVB), and lethality (LET). Serum creatine kinase-MB (CK-MB) levels were quantified, and histopathological analyses were performed to evaluate the degree of myocardial injury in the different study groups. Administration of OME prior to cardiac ischemia increased the incidence of VA, AVB, LET, and serum CK-MB levels in both NWR and SHR. In contrast, administration before cardiac reperfusion did not exacerbate cardiac injury and was associated with the attenuation of electrophysiological instability. Histopathological findings corroborated the biochemical and functional outcomes. OME, when administered prior to cardiac ischemia, worsens both cardiac arrhythmias and myocardial injury; however, administration immediately prior to cardiac reperfusion does not increase cardiac arrhythmias and decreases myocardial injury in both NWR and SHR.
- Open Access
- 1 April 2026
- Vol. 41 (2)
The Heart Surgery Trailblazer's Enduring Legacy - in Memory of Professor Enio Buffolo.
- 1 April 2026
- Vol. 41 (2)
Open AccessThe Heart Surgery Trailblazer's Enduring Legacy - in Memory of Professor Enio Buffolo.
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (4)
A Cirurgia é o Meio e não o Desfecho: Seguimento Tardio da Cirurgia de Revascularização Miocárdica
A cirurgia de revascularização do miocárdio (CRM) permanece em posição de destaque no tratamento da doença arterial coronariana (DAC), sobretudo nos subgrupos de pacientes de maior risco, como doença de múltiplos vasos, disfunção ventricular esquerda, diabetes mellitus e carga isquêmica elevada, comprovada por décadas de evidências científicas e seus resultados consistentes em longo prazo. A DAC tem evolução progressiva, sistêmica e crônica, o que torna o seguimento em longo prazo, essencial para a interpretação dos resultados nas estratégias terapêuticas. Desta
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (4)
Open AccessA Cirurgia é o Meio e não o Desfecho: Seguimento Tardio da Cirurgia de Revascularização Miocárdica
A cirurgia de revascularização do miocárdio (CRM) permanece em posição de destaque no tratamento da doença arterial coronariana (DAC), sobretudo nos subgrupos de pacientes de maior risco, como doença de múltiplos vasos, disfunção ventricular esquerda, diabetes mellitus e carga isquêmica elevada, comprovada por décadas de evidências científicas e seus resultados consistentes em longo prazo. A DAC tem evolução progressiva, sistêmica e crônica, o que torna o seguimento em longo prazo, essencial para a interpretação dos resultados nas estratégias terapêuticas. Desta
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (4)
Surgery is the Means, Not the End: Late Follow-Up of Coronary Artery Bypass Graft Surgery
Coronary artery bypass grafting (CABG) remains a leading treatment for coronary artery disease (CAD), particularly in high-risk patient subgroups such as those with multivessel disease, left ventricular dysfunction, diabetes mellitus, and high ischemic burden, as evidenced by decades of scientific evidence and its consistent long-term results. Coronary artery disease (CAD) has a progressive, systemic, and chronic evolution, which makes long-term follow-up essential for interpreting the results in therapeutic strategies. Therefore, outcomes after coronary artery bypass grafting (CABG) cannot be limited
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (4)
Open AccessSurgery is the Means, Not the End: Late Follow-Up of Coronary Artery Bypass Graft Surgery
Coronary artery bypass grafting (CABG) remains a leading treatment for coronary artery disease (CAD), particularly in high-risk patient subgroups such as those with multivessel disease, left ventricular dysfunction, diabetes mellitus, and high ischemic burden, as evidenced by decades of scientific evidence and its consistent long-term results. Coronary artery disease (CAD) has a progressive, systemic, and chronic evolution, which makes long-term follow-up essential for interpreting the results in therapeutic strategies. Therefore, outcomes after coronary artery bypass grafting (CABG) cannot be limited
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 41 (3)
Optimizing CABG in Brazil: Why Superspecialization and Personalized Care Matter Now
- 1 January 2026
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 41 (3)
Open AccessOptimizing CABG in Brazil: Why Superspecialization and Personalized Care Matter Now
- Open Access
- 1 January 2026
- Vol. 41 (1)
Is the Six-Minute Walk Test the Key to Boost Postoperative Clinical Outcomes in Cardiac Surgery?
- 1 January 2026
- Vol. 41 (1)
Open AccessIs the Six-Minute Walk Test the Key to Boost Postoperative Clinical Outcomes in Cardiac Surgery?
- Open Access
- 14 October 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
Guideline for Chronic Coronary Syndrome – 2025
- 14 October 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
Open AccessGuideline for Chronic Coronary Syndrome – 2025
- Open Access
- 28 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9488
Evaluation of Potential Molecular Targets of the Alkaloid Epiisopiloturine, Involved in Cardioprotective Effects, Using Computational Molecular Docking in an Animal Model of Cardiac Ischemia and Reperfusion
The most common cause of morbidity and death worldwide is acute myocardial infarction (AMI), which is typified by severe and deadly arrhythmias resulting from cardiac ischemia and reperfusion (CIR). We chose to investigate the possible cardioprotective activity of epiisopiloturine (EPI), an imidazole alkaloid presents in the leaves of Pilocarpus microphyllus, in an animal model of CIR in rats. Control rats were treated with 0.9% saline solution and then subjected to CIR (SS + CIR); they were compared to rats pretreated with either 10 mg/kg (EPI10 + CIR group) or 15 mg/kg EPI (EPI15 + CIR) before CIR. ECG analysis was used to assess the incidence of ventricular arrhythmias (VAs), atrioventricular block (AVB), and lethality (LET) brought on by CIR in these rats. Serum creatine kinase-MB (CK-MB) was assessed using a colorimetric assay. In comparison to the SS + CIR group, animals treated with EPI15 + CIR had lower AVB incidence, which decreased from 85.7% to 21.4%, while LET incidence decreased from 71.4% to 21.4%. In both EPI10 + CIR and EPI15 + CIR groups, serum CK-MB was lower than in SS + CIR positive controls. These findings suggest that administration of EPI (15 mg/kg) before CIR could reduce the incidences of AVB and LET, as well as cardiac injury markers, which suggests that, likely due to its antioxidant effects, EPI may be a promising drug to reduce LET in patients with severe and fatal arrhythmia due to AMI.
- 28 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9488
Open AccessEvaluation of Potential Molecular Targets of the Alkaloid Epiisopiloturine, Involved in Cardioprotective Effects, Using Computational Molecular Docking in an Animal Model of Cardiac Ischemia and Reperfusion
The most common cause of morbidity and death worldwide is acute myocardial infarction (AMI), which is typified by severe and deadly arrhythmias resulting from cardiac ischemia and reperfusion (CIR). We chose to investigate the possible cardioprotective activity of epiisopiloturine (EPI), an imidazole alkaloid presents in the leaves of Pilocarpus microphyllus, in an animal model of CIR in rats. Control rats were treated with 0.9% saline solution and then subjected to CIR (SS + CIR); they were compared to rats pretreated with either 10 mg/kg (EPI10 + CIR group) or 15 mg/kg EPI (EPI15 + CIR) before CIR. ECG analysis was used to assess the incidence of ventricular arrhythmias (VAs), atrioventricular block (AVB), and lethality (LET) brought on by CIR in these rats. Serum creatine kinase-MB (CK-MB) was assessed using a colorimetric assay. In comparison to the SS + CIR group, animals treated with EPI15 + CIR had lower AVB incidence, which decreased from 85.7% to 21.4%, while LET incidence decreased from 71.4% to 21.4%. In both EPI10 + CIR and EPI15 + CIR groups, serum CK-MB was lower than in SS + CIR positive controls. These findings suggest that administration of EPI (15 mg/kg) before CIR could reduce the incidences of AVB and LET, as well as cardiac injury markers, which suggests that, likely due to its antioxidant effects, EPI may be a promising drug to reduce LET in patients with severe and fatal arrhythmia due to AMI.
- 16 September 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (09) , e20250619
Diretriz de Síndrome Coronariana Crônica – 2025
- 16 September 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (09) , e20250619
Diretriz de Síndrome Coronariana Crônica – 2025
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 58, e14367
The body weight-walking distance product as a superior parameter in determining the VO2 on-kinetics in coronary artery disease
The 6-minute walk test is frequently used to assess the functional capacity of the cardiac disease population. Nevertheless, anthropometric differences can confound or misestimate performance, which highlights the need for new parameters. This study aimed to investigate the potential of the body weight-walking distance product (D·W) compared to the 6-minute walk test distance to predict exercise capacity measured by oxygen uptake (VO2) on-kinetics in coronary artery disease (CAD) patients. A cross-sectional study was conducted in a tertiary-care reference institution. Forty-six participants with multivessel CAD with and without left ventricular dysfunction underwent a 6-minute walk test with simultaneous use of mobile telemetric cardiopulmonary monitoring to evaluate VO2 kinetics and other cardiorespiratory responses. The Borg rating of perceived exertion for lower limb discomfort was only correlated with the D·W (P=0.007). The percent predicted and actual distance were only modestly to moderately correlated with VO2 on-kinetics (R2=0.12 and R2=0.29, P2 on-kinetics parameters were improved, showing a stronger correlation to the D·W (R2=0.49, Pd=1.32 vs d=0.84). The D·W demonstrated potential to be better than the distance walked in determining VO2 on-kinetics in participants with CAD with and without left ventricular dysfunction.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 58, e14367
Open AccessThe body weight-walking distance product as a superior parameter in determining the VO2 on-kinetics in coronary artery disease
The 6-minute walk test is frequently used to assess the functional capacity of the cardiac disease population. Nevertheless, anthropometric differences can confound or misestimate performance, which highlights the need for new parameters. This study aimed to investigate the potential of the body weight-walking distance product (D·W) compared to the 6-minute walk test distance to predict exercise capacity measured by oxygen uptake (VO2) on-kinetics in coronary artery disease (CAD) patients. A cross-sectional study was conducted in a tertiary-care reference institution. Forty-six participants with multivessel CAD with and without left ventricular dysfunction underwent a 6-minute walk test with simultaneous use of mobile telemetric cardiopulmonary monitoring to evaluate VO2 kinetics and other cardiorespiratory responses. The Borg rating of perceived exertion for lower limb discomfort was only correlated with the D·W (P=0.007). The percent predicted and actual distance were only modestly to moderately correlated with VO2 on-kinetics (R2=0.12 and R2=0.29, P2 on-kinetics parameters were improved, showing a stronger correlation to the D·W (R2=0.49, Pd=1.32 vs d=0.84). The D·W demonstrated potential to be better than the distance walked in determining VO2 on-kinetics in participants with CAD with and without left ventricular dysfunction.